BIO-TECHNE Corp (TECH)
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
American Credentials
Each credential is independently reviewed before it’s awarded · last reviewed Jun 9, 2026. How this is verified →
Financial summary
- Revenue FY2025
- $1.2B
- Net income
- $73.4M
- Total assets
- $2.6B
- Market cap
- $8.1B
- Gross margin
- 64.8%
- Operating margin
- 8.4%
- Net margin
- 6.0%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $1.2B
- Cost of revenue
- $429.4M
- Gross profit
- $790.3M
- Operating expenses
- $688.0M
- Operating income
- $102.3M
- Income tax
- $25.1M
- Net income
- $73.4M
- EPS (basic)
- $0.47
- EPS (diluted)
- $0.46
Balance sheet
- Total assets
- $2.6B
- Current assets
- $608.3M
- Total liabilities
- $639.1M
- Current liabilities
- $175.8M
- Shareholders’ equity
- $1.9B
Cash flow
- Operating cash flow
- $287.6M
- Investing cash flow
- -$35.2M
- Financing cash flow
- -$253.9M
- Net cash flow
- -$1.5M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $8.1B
- P/E ratio
- 155.7
- EPS (diluted)
- $0.46
- Dividend yield
- 0.45%
- Shares outstanding
- 113.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 8, 1989
BIO-TECHNE Corp (TECH) Stock Price
- Profitable — net income of $73.4M in FY2025.
- Revenue grew 31% from FY2021 to FY2025.
- Gross margin of 64.8%, net margin 6.0%.
- Trading near its 52-week high.
- Pays a dividend yielding about 0.45% annually.
- Valued at a price-to-earnings (P/E) ratio of 155.7.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review BIO-TECHNE Corp.
Write a review
News about BIO-TECHNE Corp
News & sentiment via Polygon.io
BIO-TECHNE Corp: frequently asked questions
Is BIO-TECHNE Corp an American company?
Yes — BIO-TECHNE Corp is an American company headquartered in Minneapolis, Minnesota. Its American-origin credentials have been independently reviewed and verified by americancompanies.com.
Where is BIO-TECHNE Corp headquartered?
BIO-TECHNE Corp is headquartered in Minneapolis, Minnesota, United States.
Is BIO-TECHNE Corp publicly traded?
Yes — BIO-TECHNE Corp is a publicly traded company. Its stock trades under the ticker symbol TECH on the NASDAQ.
What does BIO-TECHNE Corp do?
BIO-TECHNE Corp is an American Pharmaceuticals company in the Health & Beauty sector.
